drugset
drugset / Trial / NCT06727305

MTOR Inhibitors in Older Adults

NCT06727305 ↗

Phase 1/2 Recruiting 60 enrolled University of Texas Southwestern Medical Center National Institute on Aging (NIA) · collabUniversity of Maryland, Baltimore · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

Over the past decades, healthcare systems face significant challenges to meet the needs of an aging population due to progressive debility, functional decline and chronic diseases development. While there is a growing appreciation of the potential impact of mTOR inhibitors on slowing aging processes, preventing chronic disease and prolonging healthy lifespan, a major challenge in developing clinical trials to establish the clinical efficacy of mTOR inhibitors is the absence of pharmacokinetics (PK) and pharmacodynamics (PD) data in older adults. The proposed study will provide the foundation for future clinical trials assessing the role of mTOR inhibitors on aging related indications

Timeline

Start
2026-05-11
Primary completion
2027-09-01
Completion
2027-11-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Everolimus Small molecule 0.5 mg Oral
Comparator Everolimus Small molecule 1 mg Oral
Comparator Everolimus Small molecule 2 mg Oral
Comparator Sirolimus Small molecule 0.5 mg Oral
Comparator Sirolimus Small molecule 1 mg Oral
Comparator Sirolimus Small molecule 2 mg Oral

Indications

No indication recorded.